Qfix® Launches New Radiotherapy Positioning Technology for the More Precise Treatment of Breast Cancer
AVONDALE, Pa., Sept. 23, 2017
AVONDALE, Pa., Sept. 23, 2017 /PRNewswire/ — Today, Qfix announced the release of the first-in-its-class kVue™ Access 360™ G2 and Access™ Prone G2 positioning devices that promise to improve prone breast cancer treatment by significantly reducing radiation dose to healthy tissue while improving patient comfort and reproducible positioning.
By allowing breast tissue to fall away from the chest wall as patients lay face down, prone positioning can reduce radiation exposure to the heart and lungs by as much as 90%.1 Prone positioning can also improve the uniformity of dose delivery as well as treatment accuracy by reducing respiratory motion.2
The open design of the kVue Access 360 G2 and Access Prone G2 devices enhances prone breast cancer treatment through precise patient positioning and open access for greater flexibility in treatment planning. Both devices connect to the couch top of the radiotherapy machine and allow gravity to pull the breast away from the chest wall, sparing healthy tissue and creating a uniform shape that enables a more even dose distribution and improved cosmetic outcomes. Compared to other approaches that achieved successful cosmetic outcomes in 60-70% of cases, prone breast treatment with Qfix’s positioning technology resulted in successful cosmetic outcomes in 80-90% of the cases.1
Qfix’s kVue Access 360 G2 is designed to allow breast cancer treatment for both the left and right breast. This one-of-a-kind positioning solution inserts directly onto the couch top. The absence of a conventional couch top below the insert eliminates scatter and skin dose. The kVue Access 360 G2 also includes an expanded supraclavicular grid, which provides full access to treat the supraclavicular nodes in one set-up.
The Access Prone G2 device is CT and MR compatible to guide patients seamlessly from simulation through treatment. Foam padding increases patient comfort and removable inserts can be positioned for either left or right breast treatment. These inserts also feature low electron generating technology, minimizing skin dose and redefining the gold standard for low attenuating devices. The Access Prone G2 will be featured in the “Postlumpectomy Breast Irradiation in the Prone Position” course to be presented by Julia White, M.D., FACR, FASTRO, and Tina LaPaglia, B.S.R.T., R.T.(R)(T), during the 41st American Society of Radiologic Technologists (ASRT) Radiation Therapy Conference, Tuesday, September 26th, from 10:10-11:10 a.m. in the Novice Room at the Manchester Grand Hyatt in San Diego, CA.
The new kVue Access 360 G2 and Access Prone G2 devices will be on display with live demonstrations in the Qfix booth #735 during the American Society for Radiation Oncology (ASTRO) annual meeting, September 24 – 26, 2017, at the San Diego Convention Center.
Qfix (www.Qfix.com) is a world leader in radiotherapy dedicated to helping medical professionals provide the best patient care with the world’s finest positioning devices to enhance the probability of positive patient outcomes. For more information, visit www.Qfix.com.
1. Santos, Isaura. “Breast Cancer Radiation Therapy In Prone Position Reduces Toxic Side Effects.” Radiation Therapy News (2014). https://radiationtherapynews.com/2014/10/16/breast-cancer-radiation-therapy-prone-position-reduces-toxic-side-effects/
2. Buijsen, Jeroen, et al. “Prone Breast Irradiation for Pendulous Breasts.” Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 82.3 (2007): 337-40. Print; Croog, Victoria J., et al. “Accelerated Whole Breast Irradiation with Intensity-Modulated Radiotherapy to the Prone Breast.” IJROBP 73.1 (2009): 88-93. Print; DeWyngaert, J. Keith, et al. “Accelerated Intensity-Modulated Radiotherapy to Breast in Prone Position: Dosimetric Results.” IJROBP 68.4 (2007): 1251-59. Print.